Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Field K, Michael M, Leong T (2008) Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 68(3):299–317

Article  CAS  PubMed  Google Scholar 

Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y, Tsuburaya A (2010) Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 21(5):1001–1005

Article  CAS  PubMed  Google Scholar 

Japanese Gastric Cancer Association (2023) Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer 26(1):1–25

Article  Google Scholar 

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221

Article  CAS  PubMed  Google Scholar 

Kang Y-K, Boku N, Satoh T, Ryu MH, Chao Y, Kato K et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27–40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-esophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234–247

Article  CAS  PubMed  Google Scholar 

Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y et al (2011) The roles of surgical oncologists in the new era—minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology 78:343–352

Article  CAS  PubMed  Google Scholar 

Suzuki T, Tanabe K, Taomoto J, Yamamoto H, Tokumoto N, Yoshida K et al (2010) Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett 1:743–747

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oshiro Y, Takahashi K, Sasaki R, Kondo T, Sakashita S, Ohkohchi N (2013) Adjuvant surgery for advanced extrahepatic cholangiocarcinoma. World J Gastroenterol 19:6934–6938

Article  PubMed  PubMed Central  Google Scholar 

Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G (2014) Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 50:1590–1601

Article  PubMed  Google Scholar 

Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, Ohgaki K, Saeki H, Morita M, Sakaguchi Y, Maehara Y (2015) Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Res 35(1):401–406. PMID: 25550579

PubMed  Google Scholar 

Arigami T, Matsushita D, Okubo K, Sasaki K, Noda M, Kita Y, Mori S, Kurahara H, Yanagita S, Uenosono Y, Ishigami S, Ohtsuka T, Natsugoe S (2020) Clinical significance of conversion surgery for gastric cancer with peritoneal dissemination: a retrospective study. Oncology 98(11):798–806

Article  PubMed  Google Scholar 

Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K, Ohdan H (2018) The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21(2):315–323

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867

Article  PubMed  PubMed Central  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du R, Hu P, Liu Q, Zhang J (2019) Conversion surgery for unresectable advanced gastric cancer: a systematic review and meta-analysis. Cancer Invest 37(1):16–28

Article  PubMed  Google Scholar 

Molfino S, Ballarini Z, Gheza F, Portolani N, Baiocchi GL (2019) Is there a role for treatment-oriented surgery in stage IV gastric cancer? A systematic review. Updates Surg 71(1):21–27

Article  PubMed  Google Scholar 

Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S, Kwang Yang H, Ji J, Baba H, Kitagawa Y, Morita S, Nishiyama M, Kodera Y, CONVO‐GC‐1 Study Group, Federation of Asian Clinical Oncology (FACO) (2021) International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6(2):227–240

Article  PubMed  PubMed Central  Google Scholar 

Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y (2016) Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 19(2):329–338

Article  PubMed  Google Scholar 

Nishi M, Shimada M, Yoshikawa K, Takasu C, Wada Y, Tokunaga T, Nakao T, Kashihara H, Yoshimoto T, Yamashita S (2022) Propensity score-matched analysis of the short- and long-term outcomes of robotic versus laparoscopic gastrectomy for gastric cancer. Ann Surg Oncol 29(6):3887–3895

Article  PubMed  Google Scholar 

Ri M, Nunobe S, Honda M, Akimoto E, Kinoshita T, Hori S, Aizawa M, Yabusaki H, Isobe Y, Kawakubo H, Abe T (2020) Gastrectomy with or without omentectomy for cT3-4 gastric cancer: a multicentre cohort study. Br J Surg 107(12):1640–1647

Article  CAS  PubMed  Google Scholar 

Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K, Stomach Cancer Study Group of the Japan Clinical Oncology Group (2017) Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 265(2):277–283

Article  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820

Article  CAS  PubMed  Google Scholar 

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29(33):4387–4393

Article  CAS  PubMed  Google Scholar 

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH, CLASSIC Trial Investigators (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321

Article  CAS  PubMed  Google Scholar 

Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M (2022) Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer 25(1):188–196

Article  CAS  PubMed  Google Scholar 

Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T, Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hihara J, Sakamoto T, Fukagawa T, Katai H, Higuchi K, Boku N (2020) Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study. Ann Surg Oncol 27(1):284–292

Article  PubMed  Google Scholar 

Tiberio GA, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, Graziosi L, Pedrazzani C, Baiocchi GL, La Barba G, Roviello F, Donini A, de Manzoni G (2016) Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol 42(8):1229–1235

Article  CAS  PubMed  Google Scholar